We selected a list of schizophrenia candidate genes (SZGenes) using a multi-dimensional evidence-based approach.
In this study, we explored network characteristics of 160 schizophrenia candidate genes (SZGenes) that were prioritized by a multi-dimensional evidence-based gene ranking approach [11].
In this study, we used 160 SZGenes that were prioritized based on a multi-dimensional evidence-based gene ranking approach [11].
We retrieved 160 schizophrenia candidate genes prioritized in our recent work using a similar multi-dimensional evidence-based strategy [ 22].
This multi-dimensional evidence-based approach can be applied to other complex disorders having publically available high throughput data.
We used a list of 160 schizophrenia candidate genes (SZGenes) prioritized by a multi-dimensional evidence-based prioritization approach [ 61].
Using a multi-dimensional evidence-based candidate gene prioritization approach (8), the relative importance of each expanded gene was estimated based on the supported evidence from literature, genomics regions and functional roles.
Sun J. et al. (2010) [ 7] selected a list of schizophrenia candidate genes by a multi-dimensional evidence-based approach to provide a comprehensive review of the schizophrenia molecular networks.
Recently, we have performed the first gene prioritization using multi-dimensional evidence-based datasets in MDD, including association, linkage, gene expression (both human and animal studies), regulatory pathway, and literature search (both human and animal studies) [ 19].
Is it not time to support multi dimensional policy interventions to address an issue that is so evidently multi dimensional itself?
Figure 1: Multi dimensional scaling (MDS) analysis for the comparison of ADT and CRM.
